BR112019002579A2 - anticorpos biespecíficos fab monovalentes, assimétricos e tandem - Google Patents

anticorpos biespecíficos fab monovalentes, assimétricos e tandem

Info

Publication number
BR112019002579A2
BR112019002579A2 BR112019002579-0A BR112019002579A BR112019002579A2 BR 112019002579 A2 BR112019002579 A2 BR 112019002579A2 BR 112019002579 A BR112019002579 A BR 112019002579A BR 112019002579 A2 BR112019002579 A2 BR 112019002579A2
Authority
BR
Brazil
Prior art keywords
asymmetric
antibodies
monovalent
bispecific antibodies
fab bispecific
Prior art date
Application number
BR112019002579-0A
Other languages
English (en)
Inventor
Wu Chengbin
Original Assignee
Epimab Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimab Biotherapeutics, Inc. filed Critical Epimab Biotherapeutics, Inc.
Publication of BR112019002579A2 publication Critical patent/BR112019002579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Abstract

a invenção propõe anticorpos biespecíficos fab monovalen tes, assimétricos e tandem que podem ligar dois epítopos ou dois antígenos, composições que compreendem esses anticorpos, usos desses anticorpos, métodos para produzir esses anticorpos, ácidos nucleicos que codificam esses anticorpos e células hospedeiras que compreendem esses ácidos nucleicos.
BR112019002579-0A 2016-08-16 2017-08-15 anticorpos biespecíficos fab monovalentes, assimétricos e tandem BR112019002579A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/0095546 2016-08-16
CN2016095546 2016-08-16
CN2016109267 2016-12-09
CNPCT/CN2016/0109267 2016-12-09
PCT/US2017/046875 WO2018035084A1 (en) 2016-08-16 2017-08-15 Monovalent asymmetric tandem fab bispecific antibodies

Publications (1)

Publication Number Publication Date
BR112019002579A2 true BR112019002579A2 (pt) 2019-05-21

Family

ID=61197005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002579-0A BR112019002579A2 (pt) 2016-08-16 2017-08-15 anticorpos biespecíficos fab monovalentes, assimétricos e tandem

Country Status (10)

Country Link
US (1) US20190177439A1 (pt)
EP (1) EP3500301B1 (pt)
JP (1) JP7033328B2 (pt)
CN (1) CN109803682A (pt)
AU (1) AU2017312974B2 (pt)
BR (1) BR112019002579A2 (pt)
CA (1) CA3032430A1 (pt)
ES (1) ES2963385T3 (pt)
TW (1) TWI672317B (pt)
WO (1) WO2018035084A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210253741A1 (en) * 2018-07-03 2021-08-19 Ngm Biopharmaceuticals, Inc. Bispecific antibodies
AU2019370339A1 (en) * 2018-11-01 2021-06-10 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
CN109942712B (zh) * 2019-04-01 2022-12-20 华博生物医药技术（上海）有限公司 抗pd-l1/vegf双功能抗体及其用途
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
US20230002489A1 (en) * 2019-11-26 2023-01-05 Shanghai Epimab Biotherapeutics Co., Ltd. Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
EP4110818A1 (en) 2020-02-26 2023-01-04 Biograph 55, Inc. C19 c38 bispecific antibodies
GB2621482A (en) 2020-05-13 2024-02-14 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
WO2022037582A1 (zh) * 2020-08-18 2022-02-24 上海君实生物医药科技股份有限公司 抗cd3和抗cldn-18.2双特异性抗体及其用途
CA3190117A1 (en) * 2020-08-24 2022-03-03 Epimab Biotherapeutics (Hk) Limited Anti-ror1 antibodies and related bispecific binding proteins
CA3234609A1 (en) * 2021-10-15 2023-04-20 Leila M. BOUSTANY Activatable polypeptide complex
US20230174995A1 (en) * 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1910550A4 (en) * 2005-07-21 2009-11-04 Abbott Lab MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN103842383B (zh) * 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
SG2014008577A (en) 2011-08-23 2014-04-28 Roche Glycart Ag Bispecific antigen binding molecules
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
ES2923641T3 (es) * 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
EP3725812B1 (en) * 2014-03-03 2023-09-27 Academia Sinica Bi-specific antibodies and uses thereof
KR102317315B1 (ko) * 2014-08-04 2021-10-27 에프. 호프만-라 로슈 아게 이중특이적 t 세포 활성화 항원 결합 분자
AR101875A1 (es) * 2014-09-15 2017-01-18 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
NZ730054A (en) * 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016079081A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
CA3190117A1 (en) * 2020-08-24 2022-03-03 Epimab Biotherapeutics (Hk) Limited Anti-ror1 antibodies and related bispecific binding proteins

Also Published As

Publication number Publication date
TW201808999A (zh) 2018-03-16
RU2019103230A (ru) 2020-09-18
AU2017312974A1 (en) 2019-02-21
AU2017312974B2 (en) 2024-03-21
CN109803682A (zh) 2019-05-24
RU2019103230A3 (pt) 2020-11-30
EP3500301B1 (en) 2023-08-30
TWI672317B (zh) 2019-09-21
JP2019533985A (ja) 2019-11-28
WO2018035084A1 (en) 2018-02-22
US20190177439A1 (en) 2019-06-13
ES2963385T3 (es) 2024-03-26
CA3032430A1 (en) 2018-02-22
WO2018035084A8 (en) 2023-08-10
EP3500301A1 (en) 2019-06-26
EP3500301A4 (en) 2020-04-22
JP7033328B2 (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
CY1123642T1 (el) Αντισωματα enanti-pd-1
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
BR112018008904A2 (pt) anticorpos que se ligam especificamente a tim-3 e seus usos
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
UA117289C2 (uk) Мультиспецифічне антитіло
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
EA201892124A1 (ru) Днк-конструкции антител и способы их применения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]